Towards next-generation sequencing for HIV-1 drug resistance testing in a clinical setting

• Main Authors: Teo, Calesta Hui Yi, Nurul Hannah Binte Norhisham, Lee, Ogestelli Fabia, Png, Siyu, Chai, Chean Nee, Yan, Gabriel, Tang, Julian Wei-Tze, Lee, Chun Kiat
• Other Authors: School of Social Sciences
• Format: Article
• Language: English
• Published: 2023
• Subjects: Science::Medicine; Population Sequencing; Sanger
• Online Access: https://hdl.handle.net/10356/171161
• Institution: Nanyang Technological University

The HIV genotypic resistance test (GRT) is a standard of care for the clinical management of HIV/AIDS patients. In recent decades, population or Sanger sequencing has been the foundation for drug resistance monitoring in clinical settings. However, the advent of high-throughput or next-generation sequencing has caused a paradigm shift towards the detection and characterization of low-abundance covert mutations that would otherwise be missed by population sequencing. This is clinically significant, as these mutations can potentially compromise the efficacy of antiretroviral therapy, causing poor virologic suppression. Therefore, it is important to develop a more sensitive method so as to reliably detect clinically actionable drug-resistant mutations (DRMs). Here, we evaluated the diagnostic performance of a laboratory-developed, high-throughput, sequencing-based GRT using 103 archived clinical samples that were previously tested for drug resistance using population sequencing. As expected, high-throughput sequencing found all the DRMs that were detectable by population sequencing. Significantly, 78 additional DRMs were identified only by high-throughput sequencing, which is statistically significant based on McNemar's test. Overall, our results complement previous studies, supporting the notion that the two methods are well correlated, and the high-throughput sequencing method appears to be an excellent alternative for drug resistance testing in a clinical setting.